Clinical trials
Phase 3 Non-Muscle Invasive Bladder Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 8 |
| Completed | 5 |
| Recruiting | 5 |
| Terminated | 5 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| UroGen Pharma Ltd. | 4 |
| Janssen Research & Development, LLC | 3 |
| Spectrum Pharmaceuticals, Inc | 3 |
| CG Oncology, Inc. | 2 |
| Alliance for Clinical Trials in Oncology | 1 |
| AstraZeneca | 1 |
| Bioniche Life Sciences Inc. | 1 |
| Corewell Health West | 1 |
| ECOG-ACRIN Cancer Research Group | 1 |
| Endo USA Inc., a Keenova Therapeutics Company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Non-Muscle Invasive Bladder Neoplasms | 24 |
| Urinary Bladder Neoplasms | 16 |
| Carcinoma, Transitional Cell | 6 |
| Carcinoma in Situ | 3 |
| Neoplasms | 2 |
| Urologic Neoplasms | 2 |
| Neoplasms by Site | 1 |
| Urinary Bladder Diseases | 1 |
| Urogenital Neoplasms | 1 |
| Urologic Diseases | 1 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.